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ARTICLE
Siah2 control of T-regulatory cells limits anti-tumor
immunity
Marzia Scortegagna1*, Kathryn Hockemeyer2, Igor Dolgalev 2, Joanna Poźniak3, Florian Rambow3, Yan Li,
Yongmei Feng1, Roberto Tinoco 1,6, Dennis C. Otero1, Tongwu Zhang 4, Kevin Brown4, Marcus Bosenberg5,
Linda M. Bradley1, Jean-Christophe Marine3, Ioannis Aifantis2* & Ze’ev A. Ronai 1*
Understanding the mechanisms underlying anti-tumor immunity is pivotal for improving
immune-based cancer therapies. Here, we report that growth of BRAF-mutant melanoma
cells is inhibited, up to complete rejection, in Siah2−/− mice. Growth-inhibited tumors exhibit
increased numbers of intra-tumoral activated T cells and decreased expression of Ccl17,
Ccl22, and Foxp3. Marked reduction in Treg proliferation and tumor infiltration coincide with
G1 arrest in tumor infiltrated Siah2−/− Tregs in vivo or following T cell stimulation in culture,
attributed to elevated expression of the cyclin-dependent kinase inhibitor p27, a
Siah2 substrate. Growth of anti-PD-1 therapy resistant melanoma is effectively inhibited in
Siah2−/− mice subjected to PD-1 blockade, indicating synergy between PD-1 blockade and
Siah2 loss. Low SIAH2 and FOXP3 expression is identified in immune responsive human
melanoma tumors. Overall, Siah2 regulation of Treg recruitment and cell cycle progression
effectively controls melanoma development and Siah2 loss in the host sensitizes melanoma
to anti-PD-1 therapy.
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The development of immune checkpoint therapy (ICT),which unleashes an immune response against cancer, isamong the most rapid and significant advances in cancer
therapy over the past decade1,2. While responses to monotherapy
are often limited, combining ICT with targeted therapies and,
more recently, neoadjuvant therapy has been shown to be more
effective and durable, and has been extended to numerous cancer
subtypes, impacting the lives of more patients3–5. Efforts to
identify markers that help stratify responders and those at risk to
develop resistance to ICT6, will benefit from better understanding
of mechanisms underlying immune system regulation and
function.
The ubiquitin proteasome system is part of a regulatory cas-
cade that underlies spatial and temporal control of key cellular
functions in cell- and tissue-dependent manners. Ubiquitin pro-
teasome signaling controls key immune regulatory functions,
including pattern recognition receptor signaling, toll-like receptor
signaling7,8, RIG1-like receptor signaling9,10, Nod-like receptor
signaling11, STING signaling12, dendritic cell (DC) maturation
and function13–15, and T cell activation, tolerance, and auto-
immunity16. Understanding mechanisms underlying the role of
ubiquitin ligases in the control of tumor immunity is expected to
identify markers for patient stratification, and targets directing
therapeutic modalities.
The E3 ubiquitin ligase Siah2 functions to control a number of
fundamental cellular processes, including hypoxia17,18, the
unfolded protein response (UPR19), cell junction integrity20,
mitochondrial dynamics21, intracellular signaling22, cellular
metabolism23, and cell proliferation24–27. While these activities
are associated with immune cell function, direct evidence for
Siah2 regulation of anti-tumor immunity has been lacking. Global
functional profiling of the human ubiquitinome identified Siah2
as controlling type I interferon signaling28, pointing to a possible
role for Siah2 in the immune response. Here, using a genetic
mouse model of global Siah2 deletion, we show that Siah2
functions in intratumoral recruitment and cell cycle control of
T cells with the most notable impact on T regulatory cells (Tregs),
supporting a function in anti-tumor immunity.
Key in understanding the effectiveness of anti-tumor immunity
is the balance between tumor-infiltrating active and suppressive
T cells. While cytokines and chemokines play key role in the
recruitment, proliferation, and function of distinct T cell popu-
lations within tumors, other factors, intrinsic to individual sub-
populations define their ability to withstand the harsh
intratumoral environment, often characterized by low oxygen
tension and limited availability of nutrients. Notably, the sup-
pressive T cell population, Treg cells, has an advantage in sus-
taining the intratumoral milieu, reflected in greater propensity to
proliferate and exert suppressive function under harsh environ-
mental conditions, compared with the effector T cells29,30. Thus,
selective suppression of Tregs is expected to enhance anti-tumor
immunity. Here, we demonstrate that via its regulation of
p27 stability in stimulated T cells, Siah2 controls T cell pro-
liferation, which affects the availability of intratumoral Treg, but
not effector T cells, thereby enhancing effectiveness of the cyto-
toxic T cell and overall anti-tumor immunity.
Results
Enhanced anti-tumor immunity in melanoma grown in
Siah2−/− mice. To evaluate Siah2 function in the tumor envir-
onment, we injected cells of the BRAF-mutant melanoma line
YUMMER1.7 into syngeneic wild-type (WT) or Siah2−/− mice.
The YUMMER1.7 line carries a high somatic mutation burden
and is more immunogenic than the parental YUMM1.7 line31,32.
Growth of YUMMER1.7 cells was largely attenuated in Siah2−/−
relative to WT mice, (Fig. 1a), with no obvious changes in gross
tumor morphology or melanoma marker expression (Supple-
mentary Fig. 1a, b). Notably, 6 of 14 tumors (42%) grown in
Siah2−/− mice exhibited complete regression as compared with
2/14 (14%) tumors in WT mice (Fig. 1a). While melanoma
development in the first few days following tumor cell inoculation
was similar in both the WT and Siah2−/− mice, within 10–14 days
tumors began to regress in the Siah2−/− mice, while they con-
tinued growing in the WT genotype. Increasing the number
of tumor cells inoculated (from 4 × 105 to 1 × 106) abrogated the
tumor rejection phenotype in Siah2−/− mice (Supplementary
Fig. 1c), suggesting that tumor burden is a critical determinant of
effective Siah2-dependent immune cell function.
To map possible changes in the tumor microenvironment of
Siah2−/− mice that may contribute to tumor growth inhibition,
we performed RNA sequencing (RNAseq) on both WT or
Siah2−/− tumors. An enhanced inflammatory gene signature was
identified in tumors harvested from Siah2−/− relative to WT
mice, a signature characterized by upregulation of genes
implicated in the Th1 pathway and NOS2 signaling (Supplemen-
tary Fig. 1d). To further map the effect of Siah2 on immune
signaling, we performed PanCancer Immune Profiling using the
NanoString technology. Common to both RNAseq and Nano-
String analyses were increased expression of genes that function
in immune cell inflammatory and effector phenotypes (among
them, Gzmb, Gzma, Ifnγ, and Tnfα; Fig. 1b–d, Supplementary
Fig. 1d) and increased expression of genes associated with T cell
identity (i.e., the NFAT activation pathway genes Cd3γ, Cd3δ, and
Cd8α; Fig. 1b, c, Supplementary Fig. 1d). Both analyses also
showed increased expression of chemokines (Ccl4, Ccl3, Ccl2, and
Ccl5) and cytokines (Il1b and Cxcl9; Fig. 1c, d, Supplementary
Fig. 1d) in tumors from Siah2−/− mice. Nos2 was among the
most upregulated genes in Siah2−/− mice, while Ccl17, which
contribute to recruitment of CCR4+ Tregs to tumors and thus to
immunosuppression33,34, was among the most downregulated
(Fig. 1c, d). Diminished attraction of Tregs to tumors resulting
from reduced Ccl17/22 levels is consistent with improved anti-
tumor immunity and attenuated tumor growth. Accordingly,
both RNAseq and NanoString analyses revealed significantly
reduced expression of Foxp3, a Treg marker, in tumors harvested
from Siah2−/− mice, a decrease confirmed by quantitative PCR
(qPCR) analysis (Fig. 1d). Overall, these findings reveal an
increased inflammatory and activated immune phenotype in the
Siah2−/− tumor immune environment, concomitant with
reduced Treg infiltration.
Increased T effector cells and fewer Tregs in Siah2−/− mice
grown tumors. We next compared the type and quantity of
infiltrating immune cells in tumors grown in Siah2−/− and WT
littermates. Flow cytometry analysis performed on tumors col-
lected 11 days after melanoma cell inoculation, a time point when
tumors begin to shrink in Siah2−/− mice (Supplementary Fig. 2a)
revealed a comparable number (Fig. 2a) or proportion (Fig. 2b) of
CD45.2+, CD4+, CD8+, CD11b+ F4/80+, CD11c+, and CD11b+
GR1+ cells in both genotypes (Fig. 2a, b, Supplementary Fig. 2b).
However, a 3-fold increase in the T-bet+ cell population and a 2-
fold decrease in FOXP3+CD25+ cells within the CD4+ popula-
tion was seen in tumors grown in Siah2−/− mice as compared to
WT mice (Fig. 2c, d), while WT and Siah2−/− tumors showed
comparable expression of FOXP3 within the Treg cell population
(Supplementary Fig. 2c). These findings suggest that reduced
infiltration of Treg cells is accompanied by increased infiltration
of T effector cells. These observations led us to assess possible
changes in the Treg population, relative to other tumor-
infiltrating immune cell types in Siah2−/− mice.
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Immunohistochemistry confirmed a significant decrease in the
number of FOXP3+ cells, but not in the number of CD3+ cells,
within tumors grown in Siah2−/− mice (Supplementary Fig. 2d,
e). Furthermore, FOXP3-negative T cells exhibited an activated
effector phenotype, as reflected by an increase in IFNγ and
granzyme B in both CD4+ and CD8+ T cell populations that had
infiltrated tumors in Siah2−/− and WT mice (Fig. 2e–h). A
relative increase in the number of T-bet+ Th1 CD4+ cells was
seen in Siah2−/− mice (Fig. 2c), which can be cytotoxic and
produce IFNγ35. Siah2−/− mice also showed increased NOS2
expression in the macrophage population (Supplementary
Fig. 2f), further suggesting that Siah2−/− loss promotes an
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inflammatory phenotype, confirming RNAseq and NanoString
data.
We next assessed whether the less immunogenic YUMM1.7
cells also exhibit the unique tumor infiltration signature.
YUMM1.7 tumors that were collected 11 days after inoculation
were smaller in Siah2−/− relative to WT mice (Supplementary
Fig. 2g), and exhibited increased infiltration of CD4+ cells
expressing IFNγ (Supplementary Fig. 2h). YUMM1.7 tumors
grown in Siah2−/− mice also showed decreased frequency of
tumor-infiltrating Tregs (Supplementary Fig. 2i) as well as
macrophages positive for CD206 (Supplementary Fig. 2j), a
pattern recognition receptor associated with tumor immunosup-
pression. These phenotypes were accompanied with increased
frequency of the DC and macrophages expressing costimulatory
receptor CD80+ DC (Supplementary Fig. 2k). Like YUMMER1.7
tumors, percentages of tumor-infiltrating immune cells were
comparable in YUMM1.7 tumors from Siah2−/− and WT mice
(Supplementary Fig. 2l). Collectively, these findings suggest that
with the exception of Tregs, Siah2 regulates activity but not the
frequency of intratumoral immune cells.
Tumor-infiltrating cells inhibit tumor growth in Siah2−/−
mice. To determine whether Siah2 regulates cell autonomous
tumor infiltrated immune cells, bone marrow (BM) cells from
WT or Siah2−/− mice were transplanted into irradiated WT
recipient mice, and 8 weeks later both groups were injected
subcutaneously (s.c.) with YUMMER1.7 melanoma cells. Smaller
tumors were identified in mice transplanted with Siah2−/− rela-
tive to WT BM (Fig. 3a). While no differences were observed in
intratumoral infiltration of CD4+ or CD11b+ F4/80+ cells, a
notable increase in the number of CD8+ cells and a marked
decrease in Tregs were seen in Siah2−/− BM-transplanted mice
inoculated with YUMMER1.7 cells, which was accompanied by
increased NOS2 expression within tumor-infiltrating macro-
phages (Fig. 3b, c).
Similar to our observations in Siah2−/− mice, intratumoral
T cells in mice transplanted with BM from Siah2−/−mice showed
increased effector function, as reflected by increased levels of
IFNγ and TNFα produced by both CD4+ (Fig. 3d) and CD8+
(Fig. 3e) T cell populations relative to mice transplanted with WT
BM. These data confirm that intratumoral immune cells in
Siah2−/− mice are intrinsically more activated and exhibit more
pronounced inflammatory phenotypes.
To further assess how Siah2 regulates the intratumoral Treg
population, transplant experiments were performed, in which
lethally irradiated CD45.1 mice were injected with a 1:1 mixture
of BM cells from WT Thy1.1+CD45.2+ and Siah2−/− Thy1.2+
CD45.2+ mice. Eight weeks later, mice were inoculated with
YUMMER1.7 cells and tumors were collected 14 days later.
Fluorescence-activated cell sorting (FACS) analysis of tumor
cell populations revealed that among Foxp3+ cells, 40% were
Siah2−/− and 60% were Siah2 WT (Fig. 3f). Of note, prior to
tumor injection blood samples contained a comparable distribu-
tion of WT Thy1.1+ CD45.2+ and Siah2−/− Thy1.2+ CD45.2+ in
the CD4+ and CD8+ pools (Supplementary Fig. 3). Overall, these
findings indicate that Siah2 regulates a Tregs intrinsic mechanism
that promotes their intratumoral cell numbers, therefore increas-
ing Treg-dependent immunosuppression within tumors.
Reduced Tregs in Siah2−/−grown tumors by single-cell analy-
sis. To further assess Siah2-dependent changes in tumor-
infiltrating immune cell populations, we carried out single-cell
RNAseq analysis of CD45+ cells from YUMMER1.7 tumors
grown in WT or Siah2−/− mice. Data were analyzed by unsu-
pervised density-based clustering using the t-distributed Sto-
chastic Neighbor Embedding (t-SNE) algorithm, which enabled
partition of cell populations into 16 different clusters (Fig. 4a,
Supplementary Fig. 4a). Clusters 7 and 8, both containing CD8+
T cells, showed increased expression of granzyme B, while IFNγ
expression increased in cluster 8 (Supplementary Fig. 4b). Of
note, clusters representing Siah2−/− effector T cells (namely 7, 8,
and 12) and the Siah2−/− myeloid compartment (clusters 2, 6, 11,
and 17 for macrophages, and clusters 14 and 18 for DCs) showed
increased expression of genes implicated in glycolysis (Supple-
mentary Fig. 4c, Supplementary Table 2), a metabolic switch
observed in effector T cells36 and in activated DCs and proin-
flammatory macrophages37. These data confirmed that intratu-
moral immune cells in Siah2−/− mice are more activated and
proinflammatory. Analysis of number and frequency of cells in
each cluster within the CD45+ (Ptrpc-expressing) cells obtained
from WT and Siah2−/− tumors revealed a decreased percentage
of Tregs among intratumoral CD45+ cells obtained from
Siah2−/− relative to WT mice (Fig. 4b, Supplementary Table 5).
No differences were observed in cluster 2, which represents most
of the macrophage population. Yet, a notable decease seen in
smaller macrophage clusters 6 and 17 (Fig. 4b, Supplementary
Table 5) may represent a subgroup of macrophages that are either
intrinsically affected by Siah2 deletion or by Siah2−/− micro-
environment. Overall, these findings substantiate the relative
decrease in number of Foxp3+ cells in Siah2−/− tumors seen in
our FACS analysis.
The decreased frequency of tumor-infiltrating Tregs seen in
Siah2−/−mice could be attributed to alterations in the cell cycle, a
possibility consistent with reports that Siah2 loss in vitro
decreases cell proliferation24,26. Single-cell RNAseq analysis of
genes implicated in cell cycle control revealed inhibition of cell
cycle progression in all Siah2−/− immune cell clusters (Fig. 4c,
Supplementary Fig. 4d). Notably, a subset of the CD8+ T cells
(cluster 7) and Tregs (cluster 13) showed the most striking
inhibition of the cell cycle in Siah2−/− relative to WT genotypes
(Fig. 4c, Supplementary Fig. 4e). The cell cycle phenotypes seen in
tumor-infiltrating Tregs of Siah2−/− mice coincided with an
increased percentage of Treg cells in G1 of the cell cycle,
indicating a G0/G1 block (Fig. 4c). Indeed, tumor-infiltrating
Tregs from Siah2−/− mice showed a striking decrease in
proliferation (16% and 13% of them being in S and G2/M
phases, respectively), compared to tumor-infiltrating Tregs in WT
mice (32% and 26% in S and G2M, respectively). Accordingly,
Fig. 1 Siah2-deficient mice limits melanoma growth. a YUMMER1.7 melanoma cells (400,000) were injected s.c. into the flank of 5–7-weeks-old Siah2
WT or Siah2−/− male mice, and mean (lower panel) and individual (upper panel) tumor growth (volume) was measured over time (N= 14 for both
genotypes). Analysis shows complete regression (CR) at study termination. b NanoString analysis of PanCancer Immune Profiling genes in tumors from
WT and Siah2−/− mice (N = 5 for both genotypes). Heat map shows the most upregulated and downregulated pathways in Siah2−/− mice based on
comparisons of YUMMER1.7 tumors (n= 5). A total of 364 differentially expressed genes were found, with 87 downregulated and 277 upregulated in
Siah2−/− tumors. Analysis was performed 10 days after tumor injection. Cutoff applied: P < 0.05. c Volcano plot from NanoString analysis showing genes
differentially expressed in Siah2−/− versus WT tumors. Cutoff is color coded: green= P < 0.01, red= P < 0.05, grey= not significant. d q-RTPCR analysis
of indicated mRNAs from tumors collected 10 days after injection. N= 5, both genotypes. Data in a and d are presented as means ± s.e.m. Data in a were
analyzed by two-way ANOVA. Data in d were analyzed by unpaired t-test. **P < 0.005 and *P < 0.05 compared with WT.
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71% of the Treg infiltrating to tumors in Siah2−/− mice were
found to be in G1/G0, compared with 42% infiltrated tumors in
WT mice (Fig. 4c). To assess the rate of proliferation in each
cluster, we analyzed Ki67 expression (Fig. 4d). The levels of Ki67
mRNA expression were highest in clusters 8 (containing CD8+
cells), 13 (Tregs), and 17 (a small cluster of macrophages)
compared with other immune cell clusters (Fig. 4d). Notably,
among these highly proliferative clusters, Tregs exhibited a
significantly greater difference in expression of Ki67 between WT
and Siah2−/− genotypes (Fig. 4d). Further assessment of cell
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Fig. 2 Altered intratumoral effector T cells and Tregs in Siah2−/− mice. a, b Quantification of tumor-infiltrating immune cells (CD45.2+), CD4+ and
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unpaired t-test. ***P < 0.0005, **P < 0.005, and *P < 0.05 compared with WT.
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cycle-related genes identified decreased expression of E2F1
targets, including Dnmt1, within the Treg cluster (Fig. 4e,
Supplementary Fig. 4f, Supplementary Table 3), a change
observed in most immune cell clusters obtained from tumors
grown in Siah2−/− mice (Supplementary Fig. 4g).
To further establish changes in proliferation specific to Treg,
we evaluated in vivo incorporation of bromodeoxyuridine (BrdU)
in intratumoral immune cells. BrdU incorporation was traced in
intratumoral T cells, but not in NK+ cells, macrophages or DCs.
CD4+ conventional T cells and Tregs showed significantly
decreased BrdU incorporation in Siah2−/− compared to WT
mice, whereas BrdU incorporation into CD8+ cells was
comparable between genotypes (Fig. 4f). Importantly, decreased
BrdU incorporation in CD4+ conventional T cells did not alter
their frequency within tumors (Fig. 2a), as was seen for the Tregs.
These observations mark Tregs as the primary immune cell type
whose abundance was decreased in tumors from Siah2−/− mice.
The lack of decrease in number of tumor-infiltrating CD4+
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T cells could be attributable to increased expression of Cxcl9 that
was observed in Siah2−/− tumors (Fig. 1d), which could increase
T cell recruitment, compensating for decreased CD4+ T cells
proliferation. Indeed, immunohistochemical analysis revealed a
significantly lower Ki67 expression in Foxp3+ cells from tumors
grown in Siah2−/− compared to WT mice (Fig. 4g). These
observations substantiate the effect of Siah2 on Treg proliferation,
resulting in their reduced abundance upon Siah2 loss.
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Treg proliferation is associated with p27 expression. Siah2
activity has been often associated with cellular stress conditions
(i.e., hypoxia, UPR). We thus assessed whether the effect of Siah2
on cell cycle requires T cell stimulation. In monitoring the per-
centages of T cell subpopulations, the proliferation of lympho-
cytes in draining lymph nodes from tumor-bearing Siah2−/− or
WT mice was assessed prior to and following stimulation in
culture with CD3/CD28 antibodies combined with IL2. Prior to
stimulation, a significant increase in the number of CD8+ cells
and a decrease in the number of Foxp3+ cells in lymphocytes
from Siah2−/− compared to WT mice was noted (Supplementary
Fig. 5a). Notably, after 3 days of stimulation in culture, a marked
reduction in the number of Tregs obtained from Siah2−/−
compared to WT lymphocytes, relative to the changes seen in
CD8+ and CD4+ FOXP3− cells was observed (Fig. 5a, b). Flow
cytometry analysis confirmed a significant decrease in Ki67
expression in CD8+, CD4+/FOXP3−, and CD4/FOXP3+ popu-
lations in Siah2−/− relative to WT mice (Supplementary Fig. 5b),
confirming changes in cell proliferation.
Among cell cycle regulatory proteins reportedly controlled by
Siah2 during T cell activation is the cyclin-dependent kinase
inhibitor p2724,26. Analysis of p27 expression in unstimulated
lymphocytes derived from Siah2−/− or WT draining lymph
nodes revealed comparable expression (Supplementary Fig. 5c).
However, stimulated lymphocytes from Siah2−/− draining lymph
nodes showed a marked (15-fold) increase in p27 protein levels
relative to lymphocytes from WT mice (Fig. 5c), and a moderate
induction of p27 mRNA relative to WT lymphocytes (Supple-
mentary Fig. 5d). An increase in expression of cleaved caspase 3
protein (Fig. 5c) was also noted in activated lymphocytes from
Siah2−/− mice (compared to those obtained from WT mice),
suggesting that p27 upregulation also promoted apoptosis38,39.
Given that p27 induces G1 block in T cells40,41 and reduces
E2F1 transcriptional activity42, we analyzed changes in transcrip-
tion of E2F1 target genes in in vitro stimulated Siah2−/− and WT
lymphocytes. Indeed, decreased expression of the E2F1 targets
Cyclin E1, Tk1, Ki67, and Dnmt1 in Siah2−/− activated
lymphocytes compared to WT cells was observed (Fig. 5d).
Reduced levels of E2F1 target genes in the intratumoral Treg
cluster, as identified by single-cell RNAseq were also noted
(Fig. 4c). Impaired proliferation of Siah2−/− Treg cells could be
due to either an intrinsic proliferation defect or a response to
cytokines or growth factors secreted during activation. To
distinguish between these possibilities, T cells were isolated from
spleens of CD45.1+ WT mice, mixed (1:1) with T cells from
spleens of CD45.2+ Siah2−/− mice, and then stimulated (with
CD3/CD28 plus IL-2) for 3 days, followed by FACS analysis.
Notably, a lower (35%) percentage of CD45.2+ Siah2−/− Tregs
compared to 65% of CD45.1+ WT Treg cells was found within
the FOXP3+/CD4+ cell population. A small but statistically
significant decrease in frequency of CD45.2+ Siah2−/−/CD8+
cells was also noted among the CD8+ population, but not in
CD45.2+ Siah2−/− CD4+ FOXP3− cells (Fig. 5e) compared to
CD45.1+ cells. In agreement, a lower percentage (20%) of
CD45.2+ Siah2−/− cells was seen within the Ki67+FOXP3+
CD4+ cell population (Tregs) compared with 80% of CD45.1+
WT cells (Fig. 5g). In these experiments, the frequency of
CD45.2+ Siah2−/− and CD45.1+ WT cells, was largely compar-
able within Ki67+ nonTreg populations, including the Ki67+/
CD8+ and Ki67+/CD4+/FOXP3− populations, although a
modest, albeit significant, decrease in frequency of CD45.2
Siah2−/− cells was observed in the Ki67+ CD8+ population
(Fig. 5f). Collectively, these findings suggest an intrinsic cell
proliferation defect in T cells of Siah2−/− mice, in which the Treg
population is the most impacted. Immunohistochemistry analysis
showed a significant increase of p27+FOXP3+ cells (Fig. 5h) in
YUMMER1.7 melanoma tumors grown in Siah2−/− compared to
WT mice, confirming increases in levels of p27 protein in the
Siah2−/−-derived intratumoral Treg cell population and strongly
suggesting that Siah2 controls Treg proliferation via p27.
To assess the possibility that changes in Siah2 activity alter
Treg immunosuppressive capacity, we performed an in vitro
suppression assay using WT and Siah2−/− Tregs. In culture, Treg
capacity to suppress CD4+ cell proliferation did not differ
between genotypes (Supplementary Fig. 5e). Correspondingly,
intratumoral Tregs did not exhibit differences in TGFβ or IL10
production between genotypes (Supplementary Fig. 5f). Suppres-
sive function of Tregs assessed in vivo was previously shown to
differ from that assessed in culture independent of Foxp3
expression, while lack of immune suppressive function has been
linked to Treg expression of IFNγ and its receptor43,44.
Consistent with earlier studies, showing induction of IFNγ
expression upon reduced DNMT1 expression in Tregs grown
in vivo45, we identified reduced expression of the E2F1 target
gene Dnmt1 expression (Supplementary Fig. 4f) and a notable
increase in IFNγ and IFNγ receptor (IFNγR1) levels in
intratumoral Tregs from Siah2−/− compared to WT mice
(Fig. 5i). Intratumoral CD8+ and CD4+ cells exhibited increased
IFNγ levels and comparable levels of its receptor IFNγR1 in
Siah2−/− (Fig. 5i) relative to corresponding WT cells. These
findings were supported by single-cell RNAseq analysis, which
confirmed increased expression of Ifnγ and Ifnγr1 within the Treg
cluster, and decreased Nrp1 expression (Fig. 5j). Of note, as
reported for intratumoral Nrp1−/− Tregs that exhibit a Treg
fragility phenotype44 the Siah2−/− Treg cluster exhibited
increased expression of the chemokine receptor Cxcr3, a marker
of type 1 helper T cells (Fig. 5j, Supplementary Fig. 5g), and
increased expression of genes associated with the IL12/ IFNγ
pathway (Fig. 5k, Supplementary Table 4). Increased expression
of the chemokine receptor CCR846,47, along with decreased
expression of its ligand Ccl1 was seen in Tregs infiltrating to
tumors grown in Siah2−/−, compared with WT mice (Supple-
mentary Fig. 5g).
Given the decrease in Treg cell number observed in tumors
grown in Siah2−/− mice, the basal Treg frequency was assessed.
Treg population in tumor-free Siah2−/− mice revealed a mild,
albeit significant, reduction in Treg number (by 20%) in lymph
nodes and spleen (Supplementary Fig. 5h, i), prompting the
assessment of possible changes in T cell populations in thymus.
While the percentage of immature CD4+/CD8+ double-positive
Fig. 4 Reduced proliferation of tumor-infiltrating Tregs in Siah2−/− mice. a t-SNE plot of CD45+ cells from melanoma tumors collected 11 days after
inoculation of YUMMER1.7 cells into WT or Siah2−/− mice, showing different clusters. b Color-coded bars (left) and table (right) represent proportions of
cells in each cluster within CD45+ clusters fromWT and Siah2−/− tumors. c Bar graphs showing cell cycle status of T cells, based on single-cell RNAseq in
Siah2 WT and Siah2−/− cells. d Expression of Ki67 (MKi67) mRNA identified by single-cell RNAseq within indicated clusters in both genotypes. e Violin
plot comparing expression levels of E2F1-regulated genes based on single-cell RNAseq. f BrdU was injected into Siah2 WT and Siah2−/− mice-bearing
YUMMER1.7 melanoma tumors 16 h before tumor collection. Shown is BrdU incorporation by T cells, as determined by flow cytometry (n= 5). g Ki67
(red)/Foxp3(green) staining of tumors from Siah2 WT or Siah2−/− mice analyzed 11 days after melanoma cell injection (left panels), plus quantification
(right; n= 3). Scale bar, 100 μm; mean ± s.e.m. Data were analyzed by unpaired t-test in f and g, and by Wilcoxon rank-sum test in d and e. **P < 0.0005
and *P < 0.05 compared with WT.
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and CD4+ or CD8+ single-positive populations in Siah2−/−
mouse thymus remained largely unchanged (Supplementary
Fig. 5j), a small yet significant decrease in the number of
CD4+Foxp3+ cells and in Treg precursors (CD4+ CD25+ GITR+
Foxp3− cells) in thymus of Siah2−/− relative to WT mice was
seen (Supplementary Fig. 5k, l). Notably, no signs of auto-
immunity were seen in Siah2−/− mice, up to 1 year of age.
Inhibition of proliferation in Siah2−/− cells is p27 dependent.
To assess whether increased p27 protein levels observed in
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Siah2−/− cells inhibit proliferation, changes in Ki67 expression in
cultured Jurkat T cells following knockdown of Siah2 with or
without p27 knockdown were monitored (Supplementary
Fig. 6a, b). While Siah2 knockdown alone significantly increased
p27 protein levels and decreased Ki67 expression (Fig. 6a, b),
concomitant p27 knockdown rescued Ki67 expression to WT levels
(Fig. 6a, b). Furthermore, Siah2−/− Tregs isolated from spleen and
expanded in vitro showed decreased Ki67 expression relative to
Treg derived from WT mice, a decrease reversed by p27 knock-
down (Supplementary Fig. 6c, d). These data suggest that
decreased cell proliferation seen upon Siah2 knockdown or dele-
tion is p27 dependent.
Lower intratumoral Ccl17/22 expression in tumor inhibition.
Both RNAseq and NanoString analyses showed that melanoma
tumors grown in Siah2−/− mice exhibit reduced expression of
Ccl17 and Ccl22, chemokines expressed by tolerogenic DCs49,50,
along with increased expression of Cxcl9, a chemokine func-
tioning in T cell recruitment to tumor sites (Fig. 1d). These
observations were confirmed by single-cell RNAseq analysis that
revealed increased Cxcl9 expression in the Siah2−/− myeloid
compartment, and identified Ccl17 and Ccl22 expression in the
DC clusters (14 and 18; Fig. 6c, d). Indeed, a significant decrease
in Ccl17 and Ccl22 mRNA levels was confirmed in CD11c+ cells
sorted from Siah2−/−-derived tumors (Fig. 6e). To determine
whether those decreases underlie inhibition of tumor growth,
Siah2 WT mice were treated with CCL17- and CCL22 neu-
tralizing or control antibodies, 2 days after inoculating animals
with YUMMER1.7 melanoma cells. Notably, administration of
CCL17 and CCL22 antibodies led to a 30% inhibition in tumor
weight relative to treatment with control antibody (Fig. 6f). Treg
infiltration of the tumor site decreased by ~25% (Fig. 6g), con-
comitant with a 50% increase in IFNγ expression within the
CD8+-positive population (Fig. 6h). These data suggest that
CCL17 and CCl22 mediate, in part, tumor inhibition phenotypes
seen in Siah2−/− mice.
Siah2 loss synergizes with effects of anti-PD1 therapy. Pheno-
types observed in intratumoral immune cells in tumors grown in
Siah2−/− mice mirror those reported for tumor-infiltrating
immune cells following treatment with CDK4/6 inhibitors51–53.
Since treatment with CDK4/6 inhibitors potentiates anti-PD-1
ICT therapy, we asked whether Siah2−/− loss would alter the
effectiveness of anti-PD-1 ICT in mice. WT and Siah2−/− mice
were inoculated with YUMM1.7 cells and 7 days later both
groups were treated with anti-PD-1 antibody. YUMM1.7 cells
were selected since they exhibit a limited tumor inhibition fol-
lowing treatment with anti-PD1 antibodies32. Notably, Siah2−/−
mice not treated with anti-PD-1 antibody exhibited decreased
tumor growth, with one of eight tumors regressed, which was not
seen in the WT background. Significantly, treatment of Siah2−/−
mice with anti-PD1 antibodies promoted tumor regression in five
of seven animals (Fig. 6i, Supplementary Fig. 6e), while only one
of seven WT mice exhibited tumor regression in response to PD-
1 blockade (Fig. 6i, Supplementary Fig. 6e). Similarly, growth of
MC38 colon cancer cells in Siah2−/− mice was attenuated fol-
lowing administration of anti-PD-1 antibodies compared with
comparable treatment of WT mice (Supplementary Fig. 6f). These
findings demonstrate that anti-PD-1 therapy synergizes with loss
of Siah2 and promotes tumor regression.
Siah2-Foxp3 expression correlates in immunogenic specimens.
The clinical relevance of our findings was assessed by monitoring
changes in Siah2 expression in the TCGA skin melanoma cohort
(TCGA_SKCM). The signature of genes that were differentially
expressed in the Siah2−/− grown tumors was compared with
those grown in the WT mice (Fig. 1c). To focus the analysis
on immune infiltrated metastatic melanomas, the TCGA cohort
(n= 339) was stratified for “low”, “intermediate”, or “high”
immune signature expression48. The analysis of the high immune
responsive subset (n= 66) identified a positive correlation
between the expression of FOXP3, CCL22, and SIAH2 (r= 0.4,
P= 0.001; r= 0.4, P= 0.03, respectively) and a negative corre-
lation between the expression of SIAH2 and of CD8α, IFNγ, and
CXCL9 (r=−0.3, P= 0.03; P=−0.3, P= 0.05; r=−0.3, P=
0.04, respectively; Fig. 6j and Supplementary Fig. 6G). A positive
correlation between SIAH2 and FOXP3 (Tregs marker) expres-
sion suggests that findings derived from a genetic murine mela-
noma model are relevant to human tumors and that low Siah2
levels could serve as a marker to stratify patients for ICT therapy.
Discussion
Here, we identify a role for the ubiquitin ligase Siah2 in control of
intratumoral Treg proliferation and tumor infiltration. Relative to
WT mice, Siah2−/− mice inoculated with YUMMER1.7 mela-
noma cells showed a decreased number of Tregs within tumors as
well as inhibited tumor growth, up to complete regression. Our
data points to changes in Treg proliferation, suppressive function
and recruitment which collectively impact their abundance in
tumors, enabling enhanced anti-tumor immunity.
Siah2-dependent cell autonomous regulation of Tregs with
concomitant effect on immune cell activation is supported by: (i)
Single-cell RNAseq performed on immune cells infiltrating
tumors obtained from Siah2−/− or WT mice showed that cells in
the Treg cluster (#13) exhibited the most striking G1 block in
Siah2−/− relative to WT genotypes. (ii) Analysis of Ki67
Fig. 5 Increased p27, IFNγ, and IFNγR1 in intratumoral Siah2−/− Tregs. a, b Lymphocytes from draining lymph nodes of Siah2 WT and Siah2−/− mice
were cultured, stimulated with CD3/CD28 antibodies plus IL2, and 3 days later percentages of CD4+Foxp3−, CD4+Foxp3+, and CD8+ cells among
CD45+ cells were determined by flow cytometry (n= 4). c Lysates from lymphocytes stimulated as in a were immunoblotted for p27 and cleaved caspase
3 plus GAPDH as a loading control (left; n= 4). Graph at right shows represents relative intensity of p27 protein between genotypes. d qPCR analysis of
indicated transcripts from lymphocytes cultured as in a (N= 4, both genotypes). e T cells isolated from CD45.2+ Siah2−/− spleen and CD45.1 WT spleen
were cocultured (1:1), stimulated with CD3/CD28 antibodies plus IL2, and 3 days later percentages of CD45.1+ WT and CD45.2+ Siah2−/− cells in
CD4+Foxp3−, CD4+ Foxp3+, and CD8+ populations were determined by flow cytometry (n= 4). f, g The experiment was carried on as in e, and the
percentage of CD45.1+WT and CD45.2+ Siah2−/− in Ki67+ CD4+Foxp3+ g, Ki67+CD4+ Foxp3−, and Ki67+CD8+ populations f was determined by flow
cytometry (n= 4). h p27(red)/Foxp3(green) immunostaining (left panels) of tissues from tumors grown in Siah2 WT and Siah2−/− mice collected 11 days
after melanoma cell injection, plus quantification (right; n= 3). Scale bar, 100 μm. i Frequencies of tumor-infiltrating IFN-γ+ or IFNγR1+ among CD8+,
CD4+, and CD4+/CD25+ T cells 11 days after tumor inoculation and following overnight stimulation in vitro with PMA and Ionomycin (n= 5). j Expression
of indicated mRNAs, as identified by single-cell RNAseq within the Treg cluster (cluster 13) in both genotypes. k Violin plot comparing expression levels of
IL12/IFNγ-regulated genes, based on data obtained from single-cell RNAseq k; mean ± s.e.m. Data were analyzed by unpaired t-test in a–i, and by Wilcoxon
rank-sum test in j–k. ***P < 0.0005, **P < 0.005, and *P < 0.05 compared with WT.
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expression across distinct immune populations from Siah2−/− or
WT mice confirmed that the Treg population exhibited the
greatest proliferative difference between genotypes. (iii) BrdU
incorporation assays performed in vivo identified a significant
decrease in BrdU incorporation in Treg cells. (iv) A mixed BM
chimera analysis demonstrated that decreased cell number seen in
Tregs of Siah2−/− mice is due to cell-intrinsic mechanisms rather
than to activities of other immune cells.
Among immune cells that infiltrate tumors, T cells are the most
proliferative and are thus more susceptible to Siah2-dependent
control of cell cycle progression. Intratumoral Siah2−/− T cells
exhibited increased effector functions (among them, increased
expression of IFNγ, TNFα, and granzyme B), increased expres-
sion of NFAT/cell identity genes (CD3δ, CD3ε, and CD3γ), and
decreased Treg frequency. Since Siah2 loss impacts effector T cell,
we set to clarify the nature of the differential changes observed for
Tregs, in vivo. Lack of nutrients and low oxygen, both commonly
seen in the tumor microenvironment, limit proliferation of most
immune cells that depend on glycolytic metabolism. Yet, Tregs
rely mostly on oxidative phosphorylation, which provides them
with a proliferative advantage29,30 and may render them more
responsive to Siah2 deletion. Thus, among the diverse T cell
populations, the intratumoral Tregs are the most sensitive to
Siah2 deletion, reflected by the highest degree of G1 block among
tumor-infiltrated immune cell populations. While changes in cell
cycle control were previously seen in Siah2−/− derived mouse
embryonic fibroblasts54, neither their effect on T cell sub-
populations nor the mechanism underlying these changes were
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reported. Although we did not observe defects in Treg immu-
nosuppressive capacity in Siah2−/− Tregs in vitro, changes
identified in intratumoral Siah2−/− Tregs in vivo, suggest
impaired immunosuppressive function in these cell population.
The latter is supported by noting increased expression of both
IFNγ and IFNγr1, and decreased Nrp1 expression in intratumoral
Tregs of Siah2−/− mice, consistent with decreased Treg immu-
nosuppressive function in vivo previously reported44. Thus,
immunosuppressive phenotypes may be apparent only in the
context of the tumor environment. Consistent with the preferred
effect on tumor-infiltrating Treg is the observation that Siah2−/−
mice did not exhibit autoimmune or other immune-related dis-
orders (our unpublished data).
We also show changes in DCs, where Siah2 loss increased
expression of the IFNγ-induced chemokine Cxcl9, which recruits
effector T cells to a tumor site, and concomitantly decreased
expression of Ccl17 and Ccl22, chemokines that contribute to
recruitment of Tregs to tumors. Notably, cBioPortal analysis of
TCGA data relevant to CCL22 expression in melanoma patients
revealed a strong positive correlation between CCL22 and FOXP3
mRNA expression (Pearson= 0.66, Spearman= 0.77, P= 0.02).
Furthermore, levels of CCL17 mRNA correlated positively with
levels of CCL22 mRNA expression (Pearson= 0.62, P= 0.06),
findings that link our observations in Siah2−/− mice to clinical
outcomes seen in melanoma patients. Our ability to rescue, in
part, Treg recruitment and tumor growth in Siah2−/− mice
subjected to treatment with neutralizing antibodies to Ccl17 and
Ccl22 further illustrates the independent pathways by which Siah2
controls tumor growth. Additional evidence for the physiological
significance of our findings comes from analysis of human mel-
anoma tumors in the TCGA dataset. A significant positive cor-
relation between expression of SIAH2 and the immune gene
signature of tumors grown in our Siah2−/− mouse model sig-
nified the immune-responsive human melanoma tumors. The
latter substantiates the significance of our finding in murine
melanoma models and suggests potential use of Siah2 expression
as a marker to stratify melanoma cases for ICT.
The finding that reduced proliferation of T cells can be
attributed to Siah2 regulation of p27 stability is consistent with
previous reports24,26. Siah2 knockdown in the Jurkat T cells
increased p27 protein levels and decreased proliferation, changes
reversed by co-deletion of p27. Siah2-dependent effects on p27
are likely manifested following the stress accompanying immune
cell stimulation (via T cell receptor signaling) or harsh tumor
environment, conditions implicated for Siah2 activities55. Cell
cycle arrest phenotypes seen following Siah2 loss resemble those
observed following treatment with CDK4/6 inhibitors51–53.
Indeed, decreased proliferation and cell cycle arrest seen in single-
cell-based RNAseq analysis of tumor-infiltrated T cells in
Siah2−/− mice resemble changes observed following use of
pharmacological CDK4/6 inhibitors currently in clinical trials52.
Common to both is a robust increase in anti-tumor immunity.
Administration of Siah2 inhibitors could thus provide a ther-
apeutic advantage in modulating cell cycle progression in a select
immune cell population, which we show to be Tregs, and
represent a novel therapeutic modality. Although the develop-
ment of Siah2 inhibitors has been a challenging task, our findings
justify hastening those efforts.
In all, we demonstrate the ability to target tumors that are
nonresponsive to PD-1 therapy by providing an environment
limiting Treg suppressive function, as observed in the Siah2−/−
mice. Limiting Treg infiltration or suppressive function is also
expected to support CTLA4-based therapy, which does not
impact this select immune cell population56. Our data further
supports the notion that combining ICT with cell cycle-disrupting
drugs provides an effective strategy to promote an anti-tumor
response. Targeting the ubiquitin ligase Siah2, central in cell
autonomous proliferation and activity of Tregs, may thus offer
the rationale for an innovative therapeutic approach.
Methods
Animals and tumor models. All experimental animal procedures were approved
by the Institutional Animal Care and Use Committee of Sanford Burnham Prebys
Medical Discovery Institute (approval # 16–070, 17–043) and complied with all
relevant ethical regulations for animal testing and research. Siah2−/− mice were
generated as previously described54. BrafV600E/+; Pten−/−; and Cdkn2a−/− mouse
melanoma cells (YUMM1.7, YUMMER1.7) were kindly provided by Marcus
Bosenberg31,32. For tumor growth experiments, mice were injected s.c. with
400,000 YUMMER1.7 cells or 150,000 YUMM1.7 cells, or 500,000 MC38 cells,
unless otherwise noted. Tumor volumes were measured twice a week. Tumors were
collected 10–14 days after inoculation, unless otherwise noted.
BM chimeras. WT or Siah2−/− recipient mice were lethally irradiated (1000 rads)
and reconstituted by intravenous (i.v.) injection of 1 × 107 BM cells isolated from
femurs and tibias of donor WT or Siah2−/− mice. Recipients were treated with
antibiotics (trimethoprim 8 mg/ml and sulfamethoxazole 40 mg/ml in drinking
water) for 3 weeks after injection. Reconstitution was confirmed 6–8 weeks after
BM transfer, and chimeric mice were then injected s.c. with 400,000 YUMMER1.7
cells. For mixed BM chimeras, experiments were carried out as for BM chimeras,
except that irradiated mice were injected i.v. with a 1:1 mixture of Siah2 WT
Thy1.1 and Siah2−/− Thy1.2 cells, for a total 1 × 107 BM cells.
Tumor digestion. Tumors were excised, minced, and digested with 1 mg/ml col-
lagenase D (Roche) and 100 µg/ml DNase I (Sigma) at 37 °C for 1 h. Digests were
then passed through a 70-μm cell strainer to generate a single-cell suspension. Cells
were washed twice with phosphate-buffered saline (PBS) containing 2 mM ethy-
lenediaminetetraacetic acid (EDTA) and stained for flow cytometry.
Fig. 6 Siah2−/− effect on cell proliferation is p27-dependent a, b Jurkat cells were depleted of Siah2 alone or of Siah2 and p27 via infection with lentivirus
harboring indicated shRNAs. Proteins prepared were analyzed by immunoblot for p27 and GAPDH as loading control (n= 4; relative intensity of
p27 shown in the graphs) a, while RNA prepared was processed for qPCR analysis of Ki67 transcripts b. c Ccl17 and Ccl22 mRNA expression, as identified
by single-cell RNAseq within dendritic cell clusters (C14 and C18) in both genotypes. d Cxcl9 mRNA expression, as identified by single-cell RNAseq within
dendritic cell clusters (C14 and C18) in both genotypes. e Ccl17 and Ccl22 mRNA expression of CD11c+-sorted cells from tumors from both genotypes. Ten
tumors were collected per sample 11 days after YUMMER1.7 cell inoculation. Data are representative of two independent experiments. f–h Weight of
tumors collected 19 days after YUMMER1.7 cell inoculation of WT mice, which were injected i.p. with CCL17 and CCL22 neutralizing antibodies every other
day, starting 3 days after melanoma cell inoculation (n= 4) f. At the end of the treatment described in f (day 19), tumors were collected and frequencies of
tumor-infiltrating Foxp3+ cells within the CD4+ T cell population g and of IFN-γ- expressing CD8+ cells (n= 4) were determined h. i Loss of
Siah2 synergizes with PD1 therapy. Mean growth curves over time of tumors derived from YUMM1.7 cells (150,000) injected into WT and Siah2−/− mice,
which were then treated with anti-PD-1 antibody (200 μg/mouse; three times per week for a total of five times) or rat isotype (IgG) starting at day 7 after
melanoma cell injection. WT and Siah2−/− IgG (n= 8); WT and Siah2−/− anti-PD-1 antibodies (n= 7). Shown are complete regression (CR) rates at study
termination. j Positive correlation between Siah2 and Foxp3 expression in immunogenic melanoma tumors. Spearman’s rank correlation plots (scatterplots)
for pairwise comparisons between SIAH2 expression (mRNA z-scores) and the Genset identified in Treg immune signature seen in Siah2−/− mice
expressed in the metastatic samples with high immune signals from TCGA_SKCM (n= 66)48; mean ± s.e.m. Data were analyzed by Wilcoxon rank-sum
test c, d, unpaired t-test a, b, f–h or two-way ANOVA with Bonferroni multiple comparison i. ***P < 0.0005, **P < 0.005, and *P < 0.05.
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Flow cytometry. Tumor-derived single-cell suspensions were washed twice with
FACS staining buffer, fixed 15 min with 1% formaldehyde in PBS, washed twice,
and resuspended in FACS staining buffer. For intracellular cytokine staining, cells
were resuspended in complete RPMI-1640 (containing 10 mM HEPES, 1% non-
essential amino acids and L-glutamine, 1 mM sodium pyruvate, 10% heat-
inactivated fetal bovine serum (FBS), and antibiotics) supplemented with 50 U/mL
IL-2 (NCI) and 1 mg/mL brefeldin A (BFA, Sigma), and then incubated either with
phorbol myristate acetate (10 ng/ml) and ionomycin (0.5 μg/ml) or with melanoma
peptides made by Anaspec Inc at 2 μg/ml: MGP10025–33 (AS-64752); melan-A26–35,
(AS-61011); TRP2180–188, (AS-61058); and TRP2181–188 (AS-64811) for 16 h at
37 °C. Cells were then fixed and permeabilized using a Cytofix/Cytoperm Kit
(BD Biosciences) before staining.
Antibodies were purchased against the following proteins: CD45.2 (104, 1:200),
CD8α (53–6.7, 1:200), CD4 (GK1.5, 1:200), CD45.1 (A20, 1:200), TNFα (MP6-
XT22, 1:100), IFNγ (XMG1.2, 1:100), CD11c (N418, 1:200), CD11b (M1/70,
1:200), MHC class I (AF6–88.5, 1:200), CD80 (16-10A1, 1:200, 1:200), FOXP3
(FJK-16s, 1:100), CXCR3 (CXCR3-173), CCR8 (SA214G2, 1:200), GR1 (RB6-8C5,
1:200), CD206 (C068C2, 1:200), Thy1.1 (OX-7, 1:200), Thy1.2 (53-21, 1:200), KI67
(16A8, 1:100), TGFβ (TW7-16B4, 1:100), IL10 (JES516E3, 1:100), GITR (DTA-1,
1:200), TBET (4B10, 1:100), and CD25 (3C7, 1:200) were purchased from
BioLegend, while GRANZYME B (GB11, 1:10) and NOS2 (CXNFT, 1:100) were
purchased from BD Biosciences, and IFNγr1 was purchased by Miltenyi Biotec Inc
(130104934, 1:100). All data were collected on an LSRFortessa cell analyzer (BD
Biosciences) and analyzed using FlowJo Software (Tree Star). Gating strategy is
provided in Supplementary Fig. 7.
Histology and immunofluorescence. Tumors collected 11 days after melanoma
cell injection were fixed in 4% formalin overnight at 4 °C, washed with PBS, par-
affin-embedded, cut into 5 μm-thick sections and stained with hematoxylin and
eosin. For immunofluorescence, sections were deparaffinized, rehydrated, and
washed in PBS. Antigen retrieval was performed in a pressure cooker (Decloaking
chamber, Biocare Medical) in citrate buffer (pH 6.0). Foxp3 (ThermoFisher Life-
Technology FJK-165, 1:100), Ki67 (AbCam Ab15580, 1:250), CD3 (Novus Biolo-
gicals NB600-144, 1:50), and p27 (Santa Cruz; C-19, 1:25) immunostaining was
performed by incubating sections overnight at 4 °C with antibodies in Dako
antibody diluent. Alexa Fluor 488- or Alexa Fluor 594-conjugated secondary
antibodies were added for 1 h at room temperature (Molecular Probes), and nuclei
were counterstained using SlowFade Gold Antifade reagent (Vector) with 4′,6-
diamidino-2-phenylindole (DAPI, Vector).
Image data were obtained using an Olympus TH4–100 microscope and
Slidebook 4.1 digital microscopy. For quantification, Ki67-, Foxp3-, CD3-, and
p27-positive cells were counted in five random ×20 fields per mouse. Staining was
scored using a three-tiered intensity scale ranging from 0 (no staining) to ++
(highest intensity).
Cell lines and gene silencing. YUMM1.7 and YUMMER1.7 cells were kindly
provided by Marcus Bosenberg31,32 and grown in DMEM media supplemented
with 10% FBS and Amp/Pen. MC38 cell line was obtained from Kerafast and was
grown in DMEM media supplemented with 10% FBS and Amp/Pen. Jurkat cells
were obtained from ATCC and grown in RPMI supplemented with 10% FBS and
Amp/Pen. Short hairpin RNAs (shRNAs) were purchased from Sigma-Aldrich
(human Siah2 #2 TRCN0000297333; human Siah2#4 TRCN0000297339; human
p27#1 TRCN0000039928; human p27#3 TRCN0000039932; mouse p27#1
TRCN0000294885; mouse p27#2 TRCN0000287390; non targeted shRNA control;
SHC016). Lentiviral particles were prepared using standard protocols. Briefly,
HEK293T cells obtained from ATCC were transfected with shRNA plasmid and
the second-generation packaging plasmids delta R8.2 and VSV-G (Addgene). Viral
supernatants were collected 48 h later and used in the presence of polybrene
(Sigma) to infect indicated lines. Cell lines were authenticated at SBP Genomic
Core using short tandem repeat (STR) analysis which was performed on isolated
genomic DNA with the GenePrint® 10 System from Promega, and peaks were
analyzed using GeneMarker HID from Softgenetics. Allele calls were searched
against STR databases maintained by ATCC (www.atcc.org), DSMZ (www.dsmz.
de), Texas Tech University Children’s Oncology Group (cogcell.org), and the
Wistar Institute Melanoma Cell STR Profiles (http://www.wistar.org/lab/
meenhard-herlyn-dvm-dsc/page/melanoma-cell-str-profiles). All cell lines were
maintained under mycoplasma-free conditions.
Western blotting. Cells were washed once with PBS at room temperature and
resuspended in RIPA buffer (PBS containing 1% NP-40, 1% sodium deoxycholate,
1% sodium dodecyl sulfate (SDS), 1 mM EDTA, and phosphatase and protease
inhibitors), while tissue was homogenized directly in RIPA buffer. Lysates were
centrifuged, and supernatants were removed and subjected to SDS–polyacrylamide
gel electrophoresis. Proteins were transferred to nitrocellulose membranes
(Osmonics Inc., MN, USA), which were blocked and incubated with respective
primary antibodies followed by Alexa Fluor-conjugated secondary antibodies. The
first antibodies p27 (3688, 1:1000), GAPDH (5174, 1:1000), and cleaved caspase 3
(9664, 1:1000) were all purchased from Cell Signaling. Blots were imaged using an
Odyssey detection system (Amersham Bioscience, NJ, USA). Uncropped blots
provided in Source Data File.
BrdU incorporation. BrdU incorporation was performed following a protocol from
the FITC-BrdU kit (BD Pharmingen). Briefly, mice were injected intraperitoneally
(i.p.) with 1 mg BrdU solution and sacrificed 20 h later. Tumors were digested and
cells stained for surface markers. Cells were fixed and permeabilized with BD
cytofix/cytoperm buffer, followed by DNAse I digestion, and stained with anti-
BrdU antibody.
In vivo antibody treatments. Anti-CCL17 and anti-CCL22 neutralizing anti-
bodies were purchased (R&D systems). Mice were injected with both antibodies
(20 μg/dose dissolved in 200 μl sterile normal saline), starting 2 days after tumor
injection, and every other day thereafter until tumor collection. For anti-PD-1
antibody treatment, mice were injected (i.p.) with 200 μg anti-PD-1 clone RMP1-14
for YUMM1.7, and 100 μg anti-PD-1 clone RMP1-14 for MC38 cells, or rat IgG2a
isotype control on days 7, 9, 12, 14, and 16 after inoculation of YUMM1.7 cells, and
on days 7, 9, 12, and 14 after inoculation of MC38 cells.
RNA extraction and qRT-PCR analyses. Total RNA was extracted from tumors
or cells using TRIzol (Ambion) and treated with DNase I. cDNA was synthesized
using oligo-dT and random hexamer primers according to the SYBR Green qPCR
protocol (Life Technologies). Total RNA was reverse transcribed using high
Capacity Reverse Transcriptase kits (Invitrogen), according the manufacturer’s
protocol. Purity and concentration of extracted RNA were checked and quantified
by reading absorbance at 260 and 280 nm in a NanoDrop spectrophotometer
(Thermo Fisher). Quantitative real-time PCR (qRT-PCR) analyses were performed
using SYBR Green RT-PCR kits (Invitrogen) on a Bio-Rad CFX Connect Real-
Time system or Roche LightCycler. GAPDH or 18 S was amplified as an internal
control. PCR primers were designed using Primer3, and their specificity was
checked using BLAST. PCR products were limited to 100–200 bp. Primer
sequences are shown in Supplemental Table 1.
NanoString nCounter assay. For each assay, a 100 ng aliquot of RNA was mixed
with a NanoString code set mix and incubated at 65 °C overnight (16 h). Reaction
mixes were loaded onto the NanoString nCounter Prep Station for binding and
washing, and the resulting cartridge was transferred to the NanoString nCounter
digital analyzer for scanning and data collection. Quantified expression data were
analyzed using NanoString nSolver Analysis Software v2.0. After performing image
quality control using a predefined cutoff value, we excluded outlier samples using a
normalized factor based on the sum of positive control counts >3-fold. Data were
normalized by scaling with the geometric mean of built-in control gene probes for
each sample. Data tabulated in the heatmap were based on 364 DEGs (comparing
Siah2 KO to WT), of which 87 genes were downregulated and 277 were upregu-
lated, with P < 0.05. NanoString data has been deposited in public dataset: GSE
134328.
Bioinformatics and statistical analysis of the NanoString nCounter assay. For
gene expression data from the NanoString nCounter assay, filtering of samples
using quality control criteria was performed according to the manufacturer’s
recommendations. Raw counts of samples passing quality control were normalized
using 20 reference genes (Abcf1, Alas1, Edc3, Eef1g, Eif2b4, G6pdx, Gusb, Hdac3,
Hprt, Nubp1, Oaz1, Polr1b, Polr2a, Ppia, Rpl19, Sap130, Sdha, Sf3a3, Tbp, and
Tubb5) as internal controls. Data were log2-transformed and further analyzed.
Student’s t-test was applied to compare normalized expression values between
groups. IPA (Ingenuity Pathway Analysis) analysis for the 364 differentially
expressed genes (DEGs) was used to map biological processes, pathways, and
networks.
RNAseq analysis. PolyA RNA was isolated using the NEBNext® Poly(A) mRNA
Magnetic Isolation Module, and bar-coded libraries were constructed using the
NEBNext® Ultra™ Directional RNA Library Prep Kit for Illumina® (NEB, Ipswich
MA). Libraries were pooled and single end sequenced (1 × 75) on the Illumina
NextSeq 500 using the High output V2 kit (Illumina Inc., San Diego CA). Raw data
QC by FASTQC (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and
mapping to the mouse reference genome (mm10) by STAR57 with default para-
meters were performed in Illumina BaseSpace (https://basespace.illumina.com).
FeatureCounts58 was used to count reads mapped to the annotated mouse genes.
The EdgeR-based R pipeline in SARTools59 was used to identify DEGs. DEGs with
P < 0.01 and |log2Foldchange| > 2 are shown in the heatmap, and DEGs with P <
0.01 and |log2Foldchange| > 1 are included in IPA pathway analysis. Data obtained
under this analysis was deposited in public dataset: GSE134412.
Single-cell library preparation and sequencing. Siah2−/− and WT mice were
sacrificed 11 days after tumor cell inoculation. Tumors from each group were
minced prior to incubation with 0.3 Wünsch U/mL Liberase TM (Sigma) and
50 U/ml Dnase I (Roche) in Hank’s Balanced Salt Solution (Life Technologies) for
30 min at 37 °C with agitation. Tumors were homogenized by repeated pipetting
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and filtered through a 70-μm nylon filter. Single cell suspensions were washed with
1 × PBS-4%FBS before incubation 20 min on ice at 5 × 107 cells/ml with 500 ng/ml
Fc block (2.4G2, BD Pharmingen) to prevent nonspecific antibody binding. Cells
were then incubated 1 h on ice with PE-eFluor610-conjugated CD45 monoclonal
antibody (30-F11, eBioscience). For scRNAseq libraries, DAPI-negative (live)
CD45+ and CD45− cells were sorted using a SY3200 flow cytometer and sorted
cells were resuspended in RPMI for counting. Live CD45+ and CD45− cells were
mixed 5:1. Libraries were prepared using a Single Cell 3′ Reagent Kit v2, a
Chromium™ Single Cell 3′ Library & Gel Bead Kit v2, PN-120237, a Single Cell 3′
Chip Kit v2 PN-120236, and an i7 Multiplex Kit PN-120262” (10× Genomics)60,
following the user guide from the Single Cell 3′ Reagent Kit v2 (Manual Part #
CG00052 Rev A). Libraries were run on an Illumina HiSeq 4000 system as 150 bp
paired-end reads, one full lane per sample.
Single-cell RNAseq data pre-processing. Sequencing results were demultiplexed
and converted to FASTQ format using Illumina bcl2fastq software. The Cell
Ranger Single-Cell Software Suite (https://support.10xgenomics.com/single-cell-
gene expression /software/ pipelines/latest/ what-is-cell-ranger) was used to per-
form sample demultiplexing, barcode processing, and single-cell 3′ gene counting.
The cDNA insert was aligned to the mm10/GRCm38 reference genome. Only
confidently mapped, nonPCR duplicates with valid barcodes and UMIs were used
to generate the gene-barcode matrix containing 10,654 cells (4,768 Siah WT and
5,886 Siah2−/−). Further analysis, including quality filtering, identification of
highly variable genes, dimensionality reduction, standard unsupervised clustering
algorithms, and discovery of DEGs, was performed using the Seurat R package61.
To exclude low quality cells as well as cells that were extreme outliers in terms of
library complexity or that may include multiple cells or doublets, we calculated the
distribution of the number of detected genes per cell and removed cells in the
bottom and top 2% quantiles. We also removed cells with >10% of transcripts
derived from mitochondrial genes. After quality filtering, the mean and median
number of detected genes per cell was 2847.6 and 2575, respectively. After
removing unwanted cells from the dataset, we normalized the data by the total
expression, multiplied by a scale factor of 10,000, and log-transformed the result.
Integrated analysis of single-cell datasets. To account for batch differences, we
utilized the Seurat alignment method for data integration62, which does not expect
that confounding variables have uniform effects on all cells in a dataset and allows
for global transcriptional shifts between datasets. The method uses a variant of
canonical correlation analysis (CCA) to find linear combinations of features and
identifies shared correlation structures across datasets62–64. For each dataset, we
identified variable genes, while controlling for a strong relationship between
variability and average expression. We took the union of the top 2000 genes with
the highest dispersion from both datasets and ran CCA to determine common
sources of variation between the two datasets. We then aligned the subspaces based
on the first 20 canonical correlation vectors, generating a new dimensional
reduction used for further analysis. Original single-cell data has been deposited in
the public dataset, GSE 134814.
Visualization and clustering. To visualize data, we further reduced the dimen-
sionality of the entire 10075 cell dataset to project cells in two-dimensional space
using t-SNE based on the aligned CCA. Aligned CCA was also used as a basis for
partitioning the dataset into clusters using a shared nearest neighbor modularity
optimization algorithm. Using graph-based clustering, we divided cells into 19
transcriptionally similar subpopulations. We merged biologically similar clusters,
resulting in 16 defined subpopulations. We identified nonimmune populations
based on expression of Ptprc.
Determining cluster markers. To identify cluster markers, we performed pairwise
differential expression analysis using the Model-based Analysis of Single-cell
Transcriptomics (MAST) method65, adjusting for cellular detection rate, for each
cluster against all other clusters for autosomal genes detected in at least 20% of
cluster cells, keeping significant genes in each comparison. Significance was
determined using the MAST method with Bonferroni multiple-comparison cor-
rection. Immune cell types within clusters were identified based on expression of
known markers. Additionally, pathway analysis was performed for significantly
expressed genes in each cluster using Enrichr (http://amp.pharm.mssm.edu/
Enrichr/) to confirm cell types.
Cell cycle classification. We calculated a module score for each cell based on
average expression levels of G2/M and S phase markers, subtracted by the aggre-
gated expression of randomly selected control genes, as implemented in the Seurat
R package66. Each cell was assigned to the cell cycle phase with the highest positive
score, and to G1 for negative scores. The same scoring approach was also used to
quantify pathway enrichment.
T cell stimulation assay. Lymphocytes from draining lymph nodes or T cells
isolated from spleen were cultured in T-cell medium (DMEM supplemented with
10% FBS, penicillin/streptomycin, 1% HEPES, 1% nonessential amino acids, 100
mM sodium pyruvate, mercaptoethanol (1000×; SIGMA) plus 1 μg/ml of CD28
(BioLegend) and 100 U/ml rhIL-2 (Fisher Scientific) in CD3−-coated (5 μg/ml)
plates for 72 h at 37° C, at a cell density of 106/ml.
T cell isolation. Spleens were minced and passed through a 70-μm cell strainer to
generate a single-cell suspension. Red blood cells were removed by incubation in
RBC lysing buffer (Sigma). To purify CD4+ and CD8+ T cells, splenocytes were
incubated with biotinylated anti-B220 (RA3−6B2, 1:300), biotinylated anti-CD11b
(M1/70, 1:300), biotinylated anti-CD11c (N418, 1:300), biotinylated anti-CD19
(MB19-1, 1:300), biotinylated anti-CD24 (M1/69, 1:500), and anti-CD16/32 (93,
1:75), all from BioLegend for 20 min at room temperature, followed by incubation
with appropriate reagents from the EasySep mouse streptavidin RapidSpheres
isolation kit (Stem Cell Technologies), according to manufacturer’s protocol.
Collected supernatants were enriched with T cells, and the purity of CD4+ and
CD8+ cells was 92–97% based on FACS analysis.
Mouse Treg transduction. A total of 500,000 Treg cells in 96-well plate were
grown in RPMI supplemented with 10% FBS, 1% HEPES, 0.05% 2-mercap-
toethanol, and Amp/Pen in presence of IL-2 (100 U/ml) and anti-CD3 anti-CD28-
coated microbeads with bead to cell ratio 1:1. shRNAs were purchased from Sigma-
Aldrich mouse p27#12 TRCN0000071063; mouse p27#2 TRCN0000071067; non
targeted shRNA control; SHC016. Freshly collected supernatants containing len-
tiviral particles were added and supplemented with polybrene. Infection was per-
formed by centrifugation. Fresh media containing IL-2 and anti-CD3 anti-CD28-
coated microbeads was added after 24 h, along with the selective agent puromycin
(Sigma). After 48 h, the media was replaced with fresh media containing IL2 and
anti-CD3 anti-CD28-coated microbeads, and cells were collected for mRNA ana-
lysis 1 week after infection.
Mouse Treg in vitro expansion. Isolated Tregs (CD4+ CD25+ cells) were
expanded using Dynabeads mouse T activator CD3/CD28 (Gibco Life Technolo-
gies) kit and related protocol.
Treg isolation. Spleens were minced and passed through a 70-μm cell strainer to
generate a single-cell suspension. CD4-positive cells were purified using mouse
CD4+ T cell isolation kit (Easy Sep Mouse CD4+ T cell isolation kit Cat# 19852,
Stemcell), followed by sorting of Treg cells using CD4 and CD25 as markers.
DC isolation. Tumors were excised, minced, and digested with 1 mg/ml col-
lagenase D (Roche) and 100 µg/ml DNase I (Sigma) at 37 °C for 1 h. Digests were
then passed through a 70-μm cell strainer to generate a single-cell suspension.
Myeloid cells were isolated by centrifugation over the density gradient media
Lymphoprep (Axis-Shield), followed by sorting of DCs using the marker CD11c.
Treg suppression assay. CD4+ CD25− T cells and CD4+ CD25+ T cells were
purified from WT C57BL/6 mice using mouse a CD4+ T cell isolation kit (Easy Sep
Mouse CD4+ T cell isolation kit Cat# 19852, Stemcell) and an Easy Sep Mouse
CD25 Regulatory T cell positive selection kit (Cat#18782, Stemcell), and subse-
quently labeled with CFSE (Cell Trace CFSE Cell Proliferation Kit Cat# C34554
Molecular Probes, Inc). Briefly, purified T cells were suspended in PBS (+0.1%
BSA) at 107/ml with 5 µM CFSE, incubated for 10 min at 37 °C and then washed in
complete T cell medium. Purified T cells were cultured at 2 × 105/well in 96 well
plates precoated with 2 µg/ml anti-CD3 (eBioscience; 16-0031-82) and 2 µg/ml
anti-CD28 (eBioscience; 16-0281-85), along the indicated ratio (2:1, 4:1, 8:1, 16:1,
(Tconv:Treg)) of unlabeled WT or Siah2−/− CD4+CD25+ Tregs in complete T cell
medium. After 3 days of incubation, stained cells were analyzed with LSR Fortessa
X20 (Becton Dickenson).
Analysis of human melanoma tumors. Correlation of SIAH2 expression and that
of Treg signature genes identified in murine models (FOXP3, CD8A, GZMA,
GZMB, IFNG, CCL4, CCL3, CCL2, CCL5, IL1B, CXCL9, NOS2, CCL17, and
CCL22) was evaluated using Spearman’s rank correlations on high (N= 66) and
low (N= 139) immune subgroups of metastatic melanoma samples (N= 339;
TCGA_SKCM metastatic samples48). Rho and P values were used. The cutoff for
significant/suggestive correlations was R ≥ |0.2|.
Statistical Analysis. GraphPad Prism version 7 was used for statistical analysis.
Differences between two groups were assessed using two-tailed unpaired t-test or
Wilcoxon rank-sum test. Two-way analysis of variance (ANOVA) with Bonfer-
roni’s multiple comparison test was used to evaluate experiments involving mul-
tiple groups. *P < 0.05; **P < 0.01; ***P < 0.001; and ****P < 0.0001. For analysis of
human metastatic melanoma samples Rho and P values were used and the cutoff
for significant/suggestive correlations was R ≥ |0.2|.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
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Data availability
RNAseq data has been deposited in Gene Expression Omnibus (GEO) under accession
number GSE134412. NanoString data is available in GEO under accession number
GSE134328. Single-cell RNAseq data is available in GEO under accession number
GSE134814. The source data underlying Figs. 1a, c, d, 2, 3, 4c–g, 5 and 6a–i, and
Supplementary Figs. 1b, c, 2, 3, 5a, b, d–l and 6a–f are provided in the source data file.
Raw data for westerns blots is provided in the Supplementary Information. The results
shown here are in part based upon data generated by the TCGA Research Network as
part of the TCGA_SKCM data set.
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